The role of inosine pranobex in the treatment of herpes zoster and postherpetic neuralgia

Show simple item record

dc.contributor.author Payne, CME Rowland
dc.contributor.author Oakley, A
dc.contributor.author Meurisse, V
dc.contributor.author Byrom, N
dc.contributor.author Rogers, T
dc.contributor.author Hobbs, JR
dc.contributor.author Copeman, PWM
dc.contributor.author Staughton, RCD
dc.date.accessioned 2022-05-08T22:20:00Z
dc.date.available 2022-05-08T22:20:00Z
dc.date.issued 1985-07-01
dc.identifier.citation (1985). British Journal of Dermatology, 113(s29), 33-34.
dc.identifier.issn 0007-0963
dc.identifier.uri https://hdl.handle.net/2292/59054
dc.description.abstract The severity of herpes zoster worsens with age and postherpetic neuralgia is almost limited to the elderly (Wildenhoff et al., 1979, 1981). Acyclovir speeds healing and lessens pain, but has no effect on postherpetic neuralgia (Peterslund et al., 1981; Bean, Braun & Balfour, 1982). Inosine pranobex (or isoprinosine, inosiplex: trade name Imunovir), an immuno‐modulator with low toxicity, is effective in herpes simplex (Lancet, 1985). Uncontrolled observations indicate a beneficial effect in herpes zoster (Sternberg & Ruiz, 1972). We report the first double‐blind placebo‐controlled clinical trial of inosine pranobex in the treatment of herpes zoster and postherpetic neuralgia in the elderly. Forty‐two consecutive patients (19 males, 23 females) over 60‐years old and in the first 96 h of symptoms were stratified by sex, duration of pain (up to and/or over 48 h) and localization (trigeminal/other) and were randomly allocated 6 days of placebo or of inosine pranobex tablets. Five clinical and five photographic variables were monitored daily for 7–9 days (Peterslund et al., 1981). Pain was assessed monthly for a further 3 months. Investigations at entry, 1 and 4 weeks, comprised haematology, biochemistry, viral culture, immunology, including circulating T‐cell subsets, and serology, including ELISA and complement fixation tests. Results, statistically analysed by multiple regression analysis (Peterslund et al., 1981) and life‐table techniques, will be presented. Copyright © 1985, Wiley Blackwell. All rights reserved
dc.language en
dc.publisher Wiley
dc.relation.ispartofseries British Journal of Dermatology
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher.
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm
dc.subject Pain Research
dc.subject Clinical Research
dc.subject Chronic Pain
dc.subject Neurosciences
dc.subject Infectious Diseases
dc.subject Clinical Trials and Supportive Activities
dc.subject Aging
dc.subject 6.1 Pharmaceuticals
dc.subject 1103 Clinical Sciences
dc.subject 1112 Oncology and Carcinogenesis
dc.title The role of inosine pranobex in the treatment of herpes zoster and postherpetic neuralgia
dc.type Journal Article
dc.identifier.doi 10.1111/j.1365-2133.1985.tb12996.x
pubs.issue s29
pubs.begin-page 33
pubs.volume 113
dc.date.updated 2022-04-19T00:05:00Z
dc.rights.holder Copyright: The author en
pubs.end-page 34
pubs.publication-status Published
dc.rights.accessrights http://purl.org/eprint/accessRights/RetrictedAccess en
pubs.subtype Journal Article
pubs.elements-id 852107
pubs.org-id Medical and Health Sciences
pubs.org-id School of Medicine
pubs.org-id Medicine Department
dc.identifier.eissn 1365-2133
pubs.record-created-at-source-date 2022-04-19


Files in this item

Find Full text

This item appears in the following Collection(s)

Show simple item record

Share

Search ResearchSpace


Browse

Statistics